Cramer Backs Alexion Stock
All this week, Cramer compared the strongest performers of both the S&P 500 and Nasdaq and on Friday, he decided that Alexion Pharmaceuticals is the best of the bunch.
Based in Cheshire, Conn., Alexion is a biopharmaceutical company that engages in the discovery and development of biological therapeutic products for treating patients with severe and life-threatening diseases. Cramer likes its stock for many reasons, such as it has a low PEG ratio, a metric that relates growth rate to valuation. Alexion is currently trading at 1.2 times growth.
Alexion is also a prime takeover candidate, especially as big pharma companies have been hungry to snap up these kind of orphan drug developers. The company has a lot of potential, too, because its main drug could be approved for multiple new indications.
So Cramer recommends investors consider ALXN at current levels.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org